{"id":4690,"date":"2025-03-31T18:12:16","date_gmt":"2025-03-31T18:12:16","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/sodium-valproate-txt\/"},"modified":"2025-03-31T18:12:16","modified_gmt":"2025-03-31T18:12:16","slug":"sodium-valproate-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/sodium-valproate-txt\/","title":{"rendered":"sodium valproate.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nAll forms of epilepsy

DOSE IN NORMAL RENAL FUNCTION <\/H3>Oral: 600 mg \u2013 2.5 g daily in divided doses IV: For continuation of existing oral \u2014therapy, IV and oral doses are equivalent, give the same dose. For initiation of new therapy: give \u2014a loading dose of 400\u2013800 mg (up to 10 mg\/kg), followed by either a constant infusion or intermittent doses up to a cumulative daily dose of 2.5 g

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :166.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :90\u201395<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 3\u20137<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.1\u20130.41<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :6\u201315\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antidepressants: antagonise anticonvulsant effect\n
  • Anti-epileptics: concentration reduced by carbamazepine; concentration of active carbamazepine metabolite increased; increased concentration of lamotrigine, primidone, active metabolite of primidone, and possibly ethosuximide; sometimes reduces concentration of active metabolite of oxcarbazepine; alters phenytoin concentration; phenytoin and primidone reduce valproate concentration\n
  • Antimalarials: mefloquine antagonises anticonvulsant effect; increased convulsions with chloroquine and hydroxychloroquine\n
  • Antipsychotics: antagonise anticonvulsant effect; increased neutropenia with olanzapine\n
  • Ciclosporin: variable ciclosporin blood level response\n
  • Ulcer-healing drugs: metabolism inhibited by cimetidine, increased concentration

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Use solvent provided

    Route <\/H4>IV, oral, PR (unlicensed)

    Rate of Administration <\/H4>3\u20135 minutes bolus, or continuous infusion

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Increases ketones in urine. May give false positive urine tests for ketones
    Sodium valproate serum levels do not correlate with anti-epileptic activity
    Monitor serum levels to ensure not greater than 100 micrograms\/mL, or if non-compliance is suspected
    Suppositories are available on a named patient basis
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE All forms of epilepsy DOSE IN NORMAL RENAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4690","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4690"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4690\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}